C-Y Cai1, L-L Zhai2, Y Wu1, Z-G Tang3. 1. Department of General Surgery, Anhui Provincial Hospital Affiliated with Anhui Medical University, No. 17 Lujiang Road, Hefei 230001, Anhui Province, People's Republic of China; Anhui Province Key Laboratory of Hepatopancreatobiliary Surgery, No. 17 Lujiang Road, Hefei 230001, Anhui Province, People's Republic of China. 2. Department of General Surgery, Anhui Provincial Hospital Affiliated with Anhui Medical University, No. 17 Lujiang Road, Hefei 230001, Anhui Province, People's Republic of China; Anhui Province Key Laboratory of Hepatopancreatobiliary Surgery, No. 17 Lujiang Road, Hefei 230001, Anhui Province, People's Republic of China. Electronic address: jackyzhai123@163.com. 3. Department of General Surgery, Anhui Provincial Hospital Affiliated with Anhui Medical University, No. 17 Lujiang Road, Hefei 230001, Anhui Province, People's Republic of China; Anhui Province Key Laboratory of Hepatopancreatobiliary Surgery, No. 17 Lujiang Road, Hefei 230001, Anhui Province, People's Republic of China. Electronic address: tzg567@163.com.
Abstract
BACKGROUND: Peroxiredoxin-1 (Prx-1) is an important protector for redox damage and its abnormal expression is continually reported in various tumors. This study aims to investigate the expression status of Prx-1 and evaluate its clinical value in pancreatic cancer. METHODOLOGY: Immunohistochemistry was used to detect Prx-1 expression in pancreatic cancer tissues and para-cancerous tissues. Enzyme-linked immunosorbent assay (ELISA) method was applied to detect the serum Prx-1 levels. RESULTS: The immunohistochemical results indicated that positive rate of Prx-1 was (p < 0.05) higher in pancreatic cancer tissues (74.4%) than in para-cancerous tissues (37.2%). Prx-1 expression was positively correlated with vascular endothelial growth factor (VEGF) and microvessel density (MVD) in cancer tissues. The ELISA results showed that patients with pancreatic cancer had a higher serum Prx-1 level than healthy subjects (31.2 ± 13.5 vs. 13.2 ± 11.9 ng/ml, p < 0.001). Prx-1 expression was correlated with aggressive clinicopathological parameter. The combination of serum Prx-1 and CA19-9, the area under the curve (AUC) was significantly higher than Prx-1 separate. Positive Prx-1 expression was correlated with disappointing overall survival (OS) (p = 0.002) and disease-free survival (DFS) (p < 0.001). Multivariate analysis showed that Prx-1 staining as an independent biomarker of poor OS (p = 0.035) and DFS (p < 0.001). CONCLUSION: These findings suggest that the levels of Prx-1 expression are significantly increased in pancreatic cancer. The up-regulated Prx-1 is closely related to tumor angiogenesis and acts as a promising tumor marker for diagnosis and prognosis of pancreatic cancer.
BACKGROUND:Peroxiredoxin-1 (Prx-1) is an important protector for redox damage and its abnormal expression is continually reported in various tumors. This study aims to investigate the expression status of Prx-1 and evaluate its clinical value in pancreatic cancer. METHODOLOGY: Immunohistochemistry was used to detect Prx-1 expression in pancreatic cancer tissues and para-cancerous tissues. Enzyme-linked immunosorbent assay (ELISA) method was applied to detect the serum Prx-1 levels. RESULTS: The immunohistochemical results indicated that positive rate of Prx-1 was (p < 0.05) higher in pancreatic cancer tissues (74.4%) than in para-cancerous tissues (37.2%). Prx-1 expression was positively correlated with vascular endothelial growth factor (VEGF) and microvessel density (MVD) in cancer tissues. The ELISA results showed that patients with pancreatic cancer had a higher serum Prx-1 level than healthy subjects (31.2 ± 13.5 vs. 13.2 ± 11.9 ng/ml, p < 0.001). Prx-1 expression was correlated with aggressive clinicopathological parameter. The combination of serum Prx-1 and CA19-9, the area under the curve (AUC) was significantly higher than Prx-1 separate. Positive Prx-1 expression was correlated with disappointing overall survival (OS) (p = 0.002) and disease-free survival (DFS) (p < 0.001). Multivariate analysis showed that Prx-1 staining as an independent biomarker of poor OS (p = 0.035) and DFS (p < 0.001). CONCLUSION: These findings suggest that the levels of Prx-1 expression are significantly increased in pancreatic cancer. The up-regulated Prx-1 is closely related to tumor angiogenesis and acts as a promising tumor marker for diagnosis and prognosis of pancreatic cancer.
Authors: Sangeeta Jaiswal; Bishnu Joshi; Jing Chen; Fa Wang; Michael K Dame; Jason R Spence; Gina M Newsome; Erica L Katz; Yatrik M Shah; Sadeesh K Ramakrishnan; Gaoming Li; Miki Lee; Henry D Appelman; Rork Kuick; Thomas D Wang Journal: Antioxid Redox Signal Date: 2021-12-21 Impact factor: 8.401